Emergent Biosolutions
EBS
161 hedge funds and large institutions have $241M invested in Emergent Biosolutions in 2025 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 53 increasing their positions, 41 reducing their positions, and 40 closing their positions.
131% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $1.17M
37% more capital invested
Capital invested by funds: $176M → $241M (+$64.8M)
29% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 41
6.39% more ownership
Funds ownership: 66.68% → 73.07% (+6.4%)
3% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 40
0% more funds holding
Funds holding: 161 → 161 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.5M |
| 2 |
OHA
Oak Hill Advisors
New York
|
+$14.3M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.82M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$3.19M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$4.24M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.47M |
| 4 |
Goldman Sachs
New York
|
-$2.93M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.35M |
EBS Hedge Fund Activity: Q2 2025 in Review
161 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2025, worth a combined $241M — up 37% from $176M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new EBS positions and 40 closed out — a net gain of 1 holder — while 53 added to existing stakes and 41 trimmed.
The largest buyer was BlackRock, adding an estimated $14.5M. The largest seller was Millennium Management, cutting an estimated $10M.
- 161 institutional investors held Emergent Biosolutions (EBS) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $241M of Emergent Biosolutions stock for Q2 2025, up 37% quarter-over-quarter.
- 41 funds opened new Emergent Biosolutions positions in Q2 2025 and 40 closed out, a net change of +1 holder.
- The largest Emergent Biosolutions buyer in Q2 2025 was BlackRock, an estimated $14.5M added.
- The largest Emergent Biosolutions seller in Q2 2025 was Millennium Management, an estimated $10M sold.
Based on aggregated 13F filings for Q2 2025.